“REAl LIfe” observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE)

Background: Infection by SARS-CoV2 has become a challenge, especially for immunocompromised patients who show a weaker humoral response to COVID-19 vaccine. Tixagevimab+cilgavimab (Evusheld) is a combination of human monoclonal antibodies that can be used for pre-exposure prophylaxis to prevent infe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2024-10, Vol.42 (23), p.126208, Article 126208
Hauptverfasser:	Esposito, Giuliana Lucia, Fassio, Federico, Girardi, Daniela, Picasso, Erica, Meloni, Federica, Montini, Simone, Codullo, Veronica, Pattonieri, Eleonora Francesca, Defrancesco, Irene, Bianchessi, Antonio, Calvi, Monica, Seminari, Elena Maria, Baldanti, Fausto, Lilleri, Daniele, Novelli, Viola, Marena, Carlo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Viral - blood Antibodies, Viral - immunology COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Disease prevention Effectiveness Enrollments Evusheld Exposure Female Hematology Humans IgG antibody Immune response (humoral) Immune system Immunity (Disease) Immunocompromised Host Immunocompromised hosts Immunocompromised patients Immunoglobulin G Immunoglobulin G - blood Infections Male Middle Aged Monoclonal antibodies Observational studies Patients Pre-Exposure Prophylaxis - methods Prophylaxis Questionnaires SARS-CoV-2 - immunology Serology Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - immunology Transplants & implants Vaccination Vaccines Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: Infection by SARS-CoV2 has become a challenge, especially for immunocompromised patients who show a weaker humoral response to COVID-19 vaccine. Tixagevimab+cilgavimab (Evusheld) is a combination of human monoclonal antibodies that can be used for pre-exposure prophylaxis to prevent infection or disease by SARS-CoV2. Objectives: Our study aimed to investigate the effectiveness of Evusheld by comparing an Exposed and an Unexposed group. Study design: Immunocompromised patients were enrolled in the Evusheld Group between March and September 2022. All patients had anti-spike IgG antibody levels
ISSN:	0264-410X 1873-2518 1873-2518
DOI:	10.1016/j.vaccine.2024.126208